Effect of adenosine triphosphate on human coronary circulation.
We investigated in humans the effects of adenosine triphosphate (ATP), administered by intracoronary bolus (4-16 microg) or intravenous infusion (25-200 microg/kg/min), on coronary and systemic hemodynamics and electrocardiogram (ECG) variables. All patients had normal epicardial coronary arteries. The maximal coronary blood flow velocity (CBFV) was determined with intracoronary bolus of papaverine. A 12 microg bolus of ATP (n=12) caused maximal coronary hyperemia similar to that caused by papaverine. Intracoronary boluses caused a small brief decrease in arterial pressure but no significant changes in HR or ECG variables. Intravenous infusion of ATP at 150 microg/kg/min (n=15) caused a decrease in the coronary resistance index similar to that caused by papaverine, but the rate of increase in CBFV by ATP was smaller than that caused by papaverine. No patients had a significant change in ECG variables, but some patients (40%) had a serious decrease in arterial pressure. These studies suggest that maximal coronary vasodilation can be achieved safely with intracoronary ATP administration and that intravenous infusions at 150 microg/kg/min cause near-maximal coronary hyperemia in most patients.
Shiode
N
N
First Department of Internal Medicine, Hiroshima University School of Medicine.
Kato
M
M
Nakayama
K
K
Shinohara
K
K
Kurokawa
J
J
Yamagata
T
T
Matsuura
H
H
Kajiyama
G
G
D000255:Adenosine Triphosphate / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D001783:Blood Flow Velocity / Q000187:drug effects; D006328:Cardiac Catheterization; D002637:Chest Pain / Q000175:diagnosis / Q000503:physiopathology; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000503:physiopathology; D006940:Hyperemia / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D007262:Infusions, Intravenous; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000494:pharmacology; D012907:Smoking; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000633:toxicity
D014665:Vasodilator Agents; D000255:Adenosine Triphosphate; D010208:Papaverine